Luteolin-7-rutinoside exhibits both antifungal and anti-arthritic activities, potentially serving as a combination therapy for fungal arthritis caused by C. albicans infection.

Luteolin-7-rutinoside demonstrates dose-dependent immunomodulatory effects in T cells and macrophages. At concentrations of 40 μg/mL, it induces T cell proliferation at a rate comparable to that seen with 20 μg/mL, indicating a potential plateau in efficacy with increased dosage. A lower dose of 10 μg/mL (referred to as lonicerin) significantly reduces T cell proliferation by approximately 47% relative to control groups treated with Luteolin-7-rutinoside (p<0.05), highlighting its suppressive capability. Additionally, Luteolin-7-rutinoside shifts the Th1-Th2 balance towards Th2-type responses and inhibits nitric oxide (NO) production from macrophages, further evidencing its immunological influence.